UB Paderborn / Katalog / Suche / in CDI

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1505-1517

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1992-1998

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

Investigational new drugs, 2020-08, Vol.38 (4), p.1145-1155

2020

Link zum Volltext

Verfügbarkeit prüfen

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany

Lung cancer (Amsterdam, Netherlands), 2010-08, Vol.69, p.S18-S23

2010

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2010-08, Vol.69, p.S4-S10

2010

Link zum Volltext

Verfügbarkeit prüfen

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2010-08, Vol.69, p.S24-S30

2010

Link zum Volltext

Verfügbarkeit prüfen

Response to Letter to the Editor

Lung cancer (Amsterdam, Netherlands), 2011-02, Vol.71 (2), p.245-245

2011

Link zum Volltext

Verfügbarkeit prüfen

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

Current medical research and opinion, 2010-06, Vol.26 (6), p.1461-1470

2010

Link zum Volltext

Verfügbarkeit prüfen

Erstlinienbehandlung mit Cisplatin/Pemetrexed/Bevacizumab beim Pleuramesotheliom

Onkologie (Heidelberg, Germany), 2016-08, Vol.22 (8), p.598-599

Bischoff, Helge G

2016

Link zum Volltext

Verfügbarkeit prüfen

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Lung cancer (Amsterdam, Netherlands), 2012-07, Vol.77 (1), p.183-191

2012

Link zum Volltext

Verfügbarkeit prüfen

Combined Treatment of Nonsmall Cell Lung Cancer NSCLC Stage III With Intensity-Modulated RT Radiotherapy and Cetuximab: The Near Trial

Cancer, 2011-07, Vol.117 (13), p.2986-2994

2011

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092

2018

Link zum Volltext

Verfügbarkeit prüfen

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

ClinicoEconomics and outcomes research, 2012-01, Vol.4 (default), p.31-37

2012

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer” [Lung Cancer 69S1 (2010) S4–S10]

Lung cancer (Amsterdam, Netherlands), 2010, Vol.69, p.S31-S31

2010

Link zum Volltext

Verfügbarkeit prüfen

Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity‐modulated RT radiotherapy and cetuximab

Cancer, 2011-07, Vol.117 (13), p.2986-2994

2011

Link zum Volltext

Verfügbarkeit prüfen

Erstlinienbehandlung mit Cisplatin/Pemetrexed/Bevacizumab beim Pleuramesotheliom: Ergebnisse einer Phase-III-Studie

Der Onkologe, 2016-08, Vol.22 (8), p.598-599

Bischoff, Helge G.

2016

Link zum Volltext

Verfügbarkeit prüfen

PD4-3-2: Observing who performance status of patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S454-S455

2007

Link zum Volltext

Verfügbarkeit prüfen

A3-02: Observation of survival and its prognostic factors in patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S316-S316

2007

Link zum Volltext

Verfügbarkeit prüfen

Mercury (II) reduction and co-precipitation of metallic mercury on hydrous ferric oxide in contaminated groundwater

The Science of the total environment, 2016-01, Vol.539, p.36-44

2016

Link zum Volltext

Verfügbarkeit prüfen

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9582-9582

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9025-9025

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Response to Letter to the Editor

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

Erstlinienbehandlung mit Cisplatin/Pemetrexed/Bevacizumab beim Pleuramesotheliom

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma

Combined Treatment of Nonsmall Cell Lung Cancer NSCLC Stage III With Intensity-Modulated RT Radiotherapy and Cetuximab: The Near Trial

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Corrigendum to “Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer” [Lung Cancer 69S1 (2010) S4–S10]

Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity‐modulated RT radiotherapy and cetuximab

Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study

Erstlinienbehandlung mit Cisplatin/Pemetrexed/Bevacizumab beim Pleuramesotheliom: Ergebnisse einer Phase-III-Studie

PD4-3-2: Observing who performance status of patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)

A3-02: Observation of survival and its prognostic factors in patients undergoing chemotherapy for advanced non-small cell lung cancer (NSCLC)

Mercury (II) reduction and co-precipitation of metallic mercury on hydrous ferric oxide in contaminated groundwater

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER

Suchergebnisse filtern